Skip to main content
Alcohol Use Disorder (AUD)AddictionMental healthBehavioralChildren's healthBehavioral

What this study is

The goal of this clinical trial is to address the gap between clinical treatment and adolescents' lived social environments by developing and testing a novel, interactive intervention-SIM-AiR-that directly targets social risk and protective factors. By helping youth visually and cognitively process their social identities and networks, SIM-AiR seeks to support more enduring recovery outcomes in adolescents (12-19 years old) with alcohol use disorder (AUD). The specific aims of this study protocol are to pilot the SIM-AiR intervention module and collect participant acceptability feedback and preliminary outcomes. The main questions it aims to answer are:

What is the acceptability of the SIM-AiR treatment module from the perspective of participants? Do participants' acceptability ratings of the SIM-AiR treatment module vary by personal and/or social network characteristics?

Clinicians will implement the SIM-AiR with an adolescent client. Clinicians will provide feedback to the study team on their experience to support future implementation. Participants will complete the SIM-AiR module during a treatment session with their clinician and participate in data collection with study staff (e.g., surveys, interviews) following the treatment session.

What's being tested

  • SIM-AiR

    Intervention · BEHAVIORAL

    The clinician would engage the adolescent participant in the activity of social identity mapping (SIM) and use that to have a discussion, using motivational interviewing principles, about their social networks and social influences (supports, barriers) to treatment and recovery. The SIM process involves posing a series of questions to produce a visual map of the individual within their social network using paper, markers, and stickers. As this is a pilot study, this will be done once.

Study details

Sponsor
Massachusetts General Hospital
Conditions
Alcohol Use Disorder (AUD)
Enrolling
60 people
Starts
2026-08-01
Est. completion
2028-08
Design
Open-label, single group
Record
View on ClinicalTrials.gov ↗